An observational study in Small Intestinal Bacterial Overgrowth, Critical Illness and Intensive Care Unit, sponsored by University of Ioannina. Completed at 1 site in Greece. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-03-13.
Sponsored by University of Ioannina · Observational
Small intestinal bacterial overgrowth (SIBO) syndrome, though associated with potentially serious complications, has not been adequately studied to date in critically ill patients hospitalized in intensive care units (ICU).
A modified method for SIBO diagnosis is employed concerning a standard breath test. Specifically, as all participants are intubated and in need of mechanical ventilation, SIBO diagnosis is based on a non-invasive modified technique for sampling exhaled air from the ventilator tubes and performing a standard hydrogen breath test.
The primary objective of this study is assessment of the prevalence of SIBO on ICU patients. Secondary outcomes include investigation of the effects of SIBO on ventilator associated pneumonia, as well as ICU length of stay and all-cause in-hospital mortality rate in critically ill patients.
Small intestine bacterial overgrowth (SIBO) remains to this day a syndrome that is not fully understood. Initially, it was considered quite rare, but today there are reports suggesting a SIBO prevalence between 6 to 15% of healthy, asymptomatic people and reaching 80% in patients with irritable bowel syndrome. It is often involved in various disorders, such as diarrhea and malabsorption. It is defined as an increase in the number and/or disturbance in the type of bacteria in the upper part of the intestinal tract.
SIBO occurs when the homeostatic mechanisms of the small intestine are disturbed. The two main conditions that favor microbial overgrowth in the small intestine are decreased acid secretion from the stomach and small bowel dyskinesia.
The literature is scarce concerning the effects of SIBO on critically ill patients. To our knowledge this is the first study investigating the effects of SIBO on mechanically ventilated patients. It is a non-invasive observational study employing a modified technique to obtain exhaled air from the ventilator tubes to perform a standard hydrogen breath test for SIBO diagnosis. Lactulose is used as a substrate. Specifically, each patient is administered 20 g of lactulose diluted in 400 ml of water through the nasogastric tube. Measurements are performed at 0-15-30-45-60-90-120-180 min from lactulose administration. During measurements, a valve attached to a collecting bag at the end of the expiratory limb of the breathing circuit, is kept open and the collecting bag is filled by several patient exhalations. After valve closure and bag isolation, the air is drawn by a 50 ml polyethylene syringe which is connected to the valve system to prevent losses and/or contamination. Then the air is blown into the breath hydrogen monitor and the expired hydrogen measurement is recorded.
The hydrogen breath test is repeated at predetermined, protocol-based time intervals for all participants included in the study; 1st/day of admission, 3rd, 5th and 7th day of ICU stay. The 1st day measurement serves as a measure of eligibility, and patients exhibiting abnormal values of hydrogen breath testing at Day 1 are excluded from the study.
An increase by more than 20 ppm of eH2 from baseline within 90 min was considered an abnormal measurement suggesting SIBO. Moreover, an increase by more than 12 ppm of eH2 from baseline within the first 30 minutes followed by a second rise within the next 15 minutes (double peak) was also considered an abnormal measurement suggesting SIBO.
The primary objective of this study is assessment of the prevalence of SIBO on critically ill mechanically ventilated ICU patients. Secondary outcomes include investigation of the effects of SIBO on ventilator associated pneumonia, as well as ICU length of stay and all-cause in-hospital mortality rate in critically ill patients.
1,881 studies on the registry are indexed under Critical Illness; 462 are open to participants now.
This study's enrollment of 52 is below the median of 130 across 867 observational studies indexed under Critical Illness.
Browse Critical Illness studies →University of Ioannina is the lead sponsor of 53 studies on the registry; 14 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Adult critically ill patients admitted to the ICU and in need of mechanical ventilation.
Exclusion Criteria:
Adult ICU patients on mechanical ventilation
Diagnostic Test: Modified hydrogen breath test
A modified technique to obtain expired hydrogen from the ventilator tubes is performed. A connection with a valve attached to a collecting bag is inserted at the end of the expiratory limb of the breathing circuit for exhaled air collection.
Also known as: Hydrogen monitor Gastrolyzer / Gastro+TM (Bedfont® Scientific Ltd,) was used for expired hydrogen (eH2) testing.
SIBO prevalence
The proportion of ICU patients diagnosed with SIBO
Time frame: From date of ICU admission to date of ICU discharge or date of death from any cause, whichever came first, assessed up to one month)
VAP (ventilator associated pneumonia)
The proportion of ICU patients diagnosed with VAP
Time frame: From date of ICU admission to date of ICU discharge or date of death from any cause, whichever came first, assessed up to one month)
ICU LOS
ICU lenght of stay, days
Time frame: From date of ICU admission to date of ICU discharge or date of death from any cause, whichever came first, assessed up to one month)
All-cause in-hospital mortality
Death due to any cause during ICU and hospital stay.
Time frame: From date of ICU admission to date of ICU discharge or date of death from any cause, whichever came first, assessed up to one month)
Plan to share: Undecided
No publications or documents are linked to this record.
This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Ioannina